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Immunohistologic patterns in lupus nephritis: Correlations with clinical
data and prognosis. S. Berroli, A. Bucci, M. T. Porn, G. Mazzucco, P.
Stratta, P. Scalia, E. Mariani, C. Robaudo, and G. Busnach. Divisione
di Nefologia e Dialisi degli Ospedali Ca' Granda, Policlinico e S. Carlo
Borromeo, Milano, Cattedra di Nefrologia dell'Universitci, Genova,
and Cattedra di Nefrologia e Istituto di Anaromia Patologica deli' Uni-
versitd, Torino, Italy. The immunohistologic aspects in lupus nephritis
have been correlated with a few clinical parameters, but the relationship
with the presenting syndromes or the long-term clinical course has not
been fully investigated. We evaluated 122 renal biopsies in 112 patients
affected by lupus nephritis with light microscopy and immunofluores-
cence (IF). On the basis of IF, we classified them into four groups: (1)
mesangial deposits (8 cases); (2) mesangial and focal subendothelial (15
cases); (3) diffuse subendothelial (73 cases); (4) subepithelial (22 cases).
Four cases were negative. Deposits of lgG, Clq, and C3 were present in
over 75% of the cases; 1gM, between 62% and 85%; IgA and C4,
between 12% and 65% of the cases, in correlation with the severity of
the disease. A strict correspondence between IF groups and light
microscopy classes (numbered according to Appel et al) was not found.
By contrast, a good correlation between the presence and quantity of
subendothelial deposit and histologic or clinical activity was observed.
Groups 2 and 3 were characterized by different clinical syndromes:
acute nephritic syndrome was present only in group 3, whereas
nephrotic syndrome or isolated urinary abnormalities were observed in
groups 2, 3, and 4. The progression of renal failure was largely more
frequent in the diffuse subendothelial group and rare or absent in the
other groups. Death from extrarenal causes was more frequent, but not
exclusive, in that group. Within this group, a higher percent of deposits
and a higher intensity were correlated with a worse prognosis.
Hyperaldosteronism, renin-aklosterone dissociation, and increased sen-
sitivity to angiotensin II in chronic renal failure. G. Bruschi, P. Coruzzi,
A. Recusani, C. Ravanetti, L. Musiari, A. Novarini, and A. Borghelti.
IstitutodiSemeiotica Medica deIl'Università, Parma, Italy. There is no
agreement on the state of aldosterone regulation in chronic renal failure
(CRF), for reported alterations have varied from hyperaldosteronism to
hypoaldosteronism. We found plasma aldosterone concentration (PAC)
measured by radioimmunoassay to be elevated in 32 patients with CRF
(male, 20; female, 12; ages, 61 10 yr) in comparison with controls
(males, 12; female, I; ages, 52 15 yr). PAC was 27.7 35.8 ng/dl in
CRF and 5.4 4.2 in normals. Sodium intake was 50 to 60 mEq/day in
all the subjects, and all of them were in supine position. In most of the
patients, hyperaldosteronism was associated with normal or low-
normal plasma renin activity, although some had very high values
(CRF, 0.7 1.7 ng/ml/hr; controls, 0.4 0.25 ng/ml/hr). The renin-
aldosterone (R-A) dissociation of uremic patients resulted in a shifted
R-A correlation line in comparison with normal subjects. In CRF, the
metabolic efficiency of circulating aldosterone might be doubted, be-
cause of the loss of functioning renal mass. However, sodium repletion
and potassium depletion were found in 12 patients whose exchangeable
sodium and potassium were measured (exch. Na in CRF, 45.1 7.5
mEq/kg, in controls, 41.2 2.9; exch. potassium in CRF, 33.7 7.1
mEq/kg, in controls, 45.3 3.3). The stimulation of adrenal glands by
graded subpressordoses ofangiotensin (0.1, 0.2, 0.5, 1, and 2 ng/kg/min
for periods of 30 mm each) led to a more marked increase of PAC in
CRF patients than in control subjects (mean PAC in CRF, 7.0 3.7
ng/dl; in controls, 2.5 2.9 ng/dl). The possibility of artifacts must be
considered. Assay of plasma extracted with dichloromethane led to
lower PAC values, thus suggesting that water-soluble metabolites
crossreact with the antibody used; however, it failed to lower PAC
more in uremic than in normal subjects; the former still had higher
values of PAC after plasma extraction. Thus, our data suggest that, in
CRF, PAC is inappropriate to ECF volume and renin activity, possibly
being at least in part responsible for the potassium depletion and
hypertension that are frequently observed in this disease. The higher
PAC in CRF may be due either to impaired aldosterone metabolism by
renal tissue, or to increased adrenal production, possibly by known or
unknown factors in the uremic environment.
Platelet-activating factor, a mediator of platelet aggregation: Effect of
corticosteroids. G. Camussi, F. Bussolino, C. Tetta, M. C. Deregibus,
G. Segoloni, R. Ragni, andA. Vercelione. Laboratorio dilmmunopato-
logia e Cattedra di Nefrologia dell'Università, Tonino, Italy. Platelet-
activating factor (PAF), recently identified as l-0-alkyl-2-acetyl-sn-
glyceryl-3-phosphorylcholine, has been shown to be a mediator of
inflammation, which causes in vitro and in vivo platelet activation. PAF
release has been obtained from different cellular types: polymorphonu-
clear neutrophils, monocytes, macrophages, basophils, and platelets
themselves. One x 10_il M of PAF determines rabbit and human
platelet aggregation and "release reaction" independently from ADP-
and arachidonic acid- (AA) mediated pathways. PAF-dependent plate-
let activation requires Ca±* and metabolic energy, the activa-
tion of serine esterase, and a membrane phospholipase A2. Prostacy-
din, which increases intracellular cAMP levels, inhibits platelet aggre-
gation induced by PAF. We have studied the effect of membrane-active
drugs and corticosteroids on platelet aggregation induced by PAF.
Xilocaine (I0- M), mepacrine (l0 M), which are membrane active
drugs, and reserpine (5 x l0- M), imipramine (5 x l0 M), which
protect red blood cells from hypotonic lysis, were strong inhibitors of
PAF-induced platelet aggregation similarly to 6-methyl prednisolone (6-
MP) (5 x l0- M) and hydrocortisone (5 >< I0 M). These corticoste-
roids prevented the PAF-platelet interaction in a dose-dependent mode
and were uneffective on ADP- or AA-mediated pathways. Dexametha-
sone (5 x i0 M), which shows greater antiinflammatory potency than
6-MP, inhibited (50%) the action of PAF only at high doses. Intravenous
injection of PAF (0.8 g/kg) in rabbits induced dramatic and reversible
thrombocytopenia, similar to that occurring during IgE-induced sys
temic anaphylaxis or after injection of immune-complex (IC). Previous
administration of 20mg/kg of 6-MP prevented PAF induced thrombocy-
topenia. Our studies demonstrate that corticosteroids are inhibitors of
PAF activity in vitro and in vivo and provide a plausible rationale for
the empiric use of high doses of corticosteroids in patients with
thrombocytopenia occurring in anaphylactic shock and in the acute
phase of systemic lupus erythematosus.
Immune-induced leukopenia: A role for the aggregation of polymor-
phonuclear neutrophils in systemic lupus erythematosus. G. Camussi, G.
Segoloni, C. Tetta, F. Bussolino, P. Stratta, R. Ragni, and A. Vercel-
lone. Laboratorio di Immunopatologia e Cattedra di Nefrologia deli'-
Universitd, Torino, and Divisione d Nefrologia e Dialisi, Ospedale 5G.
Battista, Torino, Italy. The pathogenesis of leukopenia such as that
occurring during SLE, a human model of immune complex (IC) disease,
has been related to the intravascular aggregation of polymorphonuclear
neutrophils (PMN) with attendant leukostasis and leukoembolization in
the capillary network as a mechanism of tissue injury. Beside CSa
anaphylatoxin, in vitro IC-induced PMN aggregation is also brought
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about by cationic proteins (CP) released from IC-stimulated PMN
through their surface receptors for the Fc fragment of complexed
immunoglobulin and the C3b complement fraction. However, in vivo
both C5a and CP are rapidly cleaved to low molecular weight, desargin-
ated products, C5a des Arg, and CP des Arg, that, although devoid of
anaphylatoxin activity, exhibit a striking potentiation of their native
molecules' aggregating activity on PMN. Recently, we showed that
PMN aggregation induced by C5a, CP, C5a des Arg, and CP des Arg is
mediated by a final common effector substance, a low molecular weight
phospholipid with a biologic activity, physicochemical characteristics,
and behavior on thin layer chromatography identical to antigen-stimu-
lated, IgE-sensitized rabbit basophil-derived platelet-activating factor(PAF), initially described as a mediator of anaphylaxis capable of
inducing platelet aggregation and release of their granular content. PAF
itself is a potent inducer of PMN aggregation, which, as for platelets, is
independent from the other known pathways of aggregation, that is, the
ADP and arachidonic acid/thromboxane A2-mediated pathways of
aggregation. In vivo studies in rabbits injected with IC, C5a, and CP
have shown that the acute neutropenia is related to the intravascular
aggregation of PMN leading to their massive accumulation in the
pulmonary capillary network, a series of phenomena that have been
temporally and quantitatively correlated with the recovery of PAF in
the plasma. In systemic lupus erythematosus (SLE), leukopenia is
commonly assumed as an index of disease activity. We studied 10 SLE
patients in the clinically active phase of the disease and found leukope-
nia (WBC, 4000/mm3) in 40%. The possibility that the mechanisms
implicated in vitro and in vivo in the rabbit may be operating in man has
been indirectly suggested by the following observations: the in vivo
interaction between IC and PMN surface receptors as detected with our
immunohistologic technique; the in vivo release of CP; the depletion of
releasable PAF from PMN and their in vitro unresponsiveness to the
aggregating stimuli such as C5a, CP, C5a des Arg, CP des Arg and PAF;
the in vivo extraction of PAF from plasma during the neutropenia
associated with the active phases of SLE, However, some consider-
ations are in order. Although the IC-PMN interaction well correlated
with the clinically evident activity of the disease, the same did not hold
true for the neutropenia. The lack of correlation may be explained in
view of the fact that soluble factors rather than IC have a major bearing
on the pathogenesis of neutropenia. The in vitro unresponsiveness of
PMN to the aggregating stimuli may reflect an in vitro masking of
surface receptors or a state of metabolic overstimulation.
Neurosympathetic response to hemodialysis in patients with or without
dialysis-induced hypotension. G. Cannella, G. B. Picotti, M. D. Galva,
G. Gregorini, R. Majorca. Divisione di Nefrologia Spedali Civili,
Brescia; Istituto di Farmacologia, Facoltd di Medicina dell'Universitâ
di Milano, Italy. Six normotensive (N) and six dialysis-hypotension
prone (H) uremic patients were studied. They were submitted, during
an interdialysis day, to a postural test (5 mm upright) and on the
following day to a regular dialysis (D) lasting 3 hr. Blood samples for
radioenzymatic assay of plasma norepinephrine (NE) were drawn
before and after standing and before, during (every 40 mm), and after
dialysis. Results. Resting NE in H group was significantly higher than in
N group either before standing or before dialysis. After 5 mm upright,
NE rose in both N and H group and to a similar extent than in 12 healthy
subjects taken as control. During D, plasma NE rose continuously in
both groups, significantly after about 80 mm, in a similar way than in 6
controls, volume-depleted by furosemide injection (1 mg/kg of body wt,
i.v.). Body weight, plasma proteins, hematocrite behaved in a similar
way, during hemodialysis, in both uremic groups, whereas a significant
decrease in blood pressure was observed earlier in the H group.
Conclusions. Dialysis hypotension does not seem to depend on a
neurosympathetic deficiency but appears to be related to a hypotensive
effect borne by dialysis itself. Such a hypotensive stimulous might be
prevailing in some patients rather than in others, leading perhaps to a
chronic neurosympathetic stimulation with higher than normal plasma
NE levels.
Prognosis of acute rejection requiring dialysis. A. Cantaluppi, A. De
Vecchi, A. Tarantino, G. Banfi, G. Montagnino, and C. Ponticelli.
Divisione di Nefrologia e Dialisi, Ospedale Policlinico, Milano, Italy.
In 224 renal transplant recipients, 114 early rejection episodes have
been diagnosed within 1 month after transplantation; 32 out of them
complicated by renal insufficiency requiring dialytic treatment within 4
days since onset has been defined "acute anuric rejection episodes."
These episodes appeared within the 2nd and the 29th day after
transplantation, and were characterized by increasing proteinuria (62%
of cases), fever (56%), thrombocytopenia (31%), arterial hypertension
(28%), and reduced natriuresis (25%). The incidence of this last sign
only was significantly different (lower) as compared to natriuresis
observed in early nonanuric acute rejections. Renal bioptic findings in
13 cases were: "slight" rejection (1), "moderate" rejection (6), "se-
vere" rejection (4), and "irreversible" rejection (2). In 24 cases (75%), a
partial (16%) or total (59%) recovery of renal function allowed with-
drawal of dialytic treatment, while 8 patients had their allograft re-
moved. Prognosis was not correlated with any clinical or biochemical
data or with anuria's length. On the contrary, bioptic findings have
useful prognostic indications, 7 out of 7 patients with a "slight" or
"moderate" rejection had a recovery of renal function while only in 1
out of 6 patients with "severe" or "irreversible" rejection renal failure
reversed. As a whole, either short-term or long-term prognosis of
"acute anuric rejection episodes" did not significantly differ from that
of acute early rejection episodes. In conclusion, our data underline that
oligoanuria during an early acute rejection episode does not constitute a
negative prognostic sign, being not necessarily an expression of rejec-
tion severity.
Glomerular dynamics in pregnant rats: A micropuncture study. A. Dal
Canton, G. Conte, C. Esposito, G. Fuiano, R. Guasco, D. Russo, M.
Sabbatini, F. Uccello, and V. E. Andreucci. Cattedra di Nefrologia
Medica, Seconda Facoltà di Medicina, Universitâ, Napoli, Italy.
Although a marked rise in GFR in pregnancy has been repeatedly
noticed in the past 30 years, the mechanisms responsible for this
phenomenon have not yet been clarified. In the present study glomeru-
lar dynamics were investigated by micropuncture in pregnant Wistar-
Munich rats. Nonpregnant rats were used as controls. Glomerular
capillary pressure (P0), intratubular pressure (PT), and pressure in the
1st-order peritubular capillaries were measured with a servo-nulling
device. Single nephron filtration rate (SNGFR) was measured as the
clearance of chemical inulin in single nephrons. Single nephron filtra-
tion fraction (SNFF) was calculated from arterial and peritubular blood
protein concentration. Afferent arteriole blood flow, that is, glomerular
blood flow (GBF), resistance of single afferent (Rn) and efferent
arteriole (Re), effective filtration pressure at the afferent end (EFPa),
and at the efferent end (EFPC) of the glomerulus, and the ultrafiltration
coefficient (Kf) were calculated. In pregnant rats SNGFR increased
from 27.7 to 43.2 nl/min/g of kidney wt as a mean. R was markedly
reduced, accounting for a rise both in GBF (from 155.3 to 257.6 nl/min/g
of kidney wt) and in P0 (from 45.3 to 53.4 mm Hg). Because PT was
unchanged, EFPa rose proportionally to P0; also EFPC was increased
from a control value not different from zero to 13.2 mm Hg. This
filtration pressure disequilibrium allowed calculation of a definite value
of Kf (0.037 nllmm Hg/sec) in pregnant rats. Minimum possible value of
Kin control rats was 0.044 nI/mm Hg/sec. Pregnancy caused no change
Ifl Re or in SNFF. These results show that SNGFR is enhanced in
pregnancy due to an increase both in effective filtration pressure and in
glomerular plasma flow. The rise in SNGFR is partially opposed by a
reduction in Kf.
Some aspects of circulating immune complexes in primary glomerulo-
nephritis. P. Dall'Aglio, G. Balestrieri, L. Allegri, C. Chizzolini, E.
Ciccone, D. Pagani, and A. Tincani. Cattedra di Immunologia Clinica
e Istituto di Clinica Medica e Nefrologia dell' Universial, Parma e
Servizio di Immunologia Clinica, Spedali Civili, Brescia, Italy. In 103
patients with different biological types of primary glomerulonephritis
(PGN), we investigated circulating immune complexes (CIC) simulta-
neously in minimal change GN (MCGN) (14 cases), focal glomerulo-
sclerosis (FGS) (9 cases), membranous GN (MGN) (19 cases), mem-
branoproliferative GN (MPGN) (23 cases), mesangioproliferative GN
(MSPGN) (28 cases), 18 of these with mesangial predominant IgA
deposits. We used three tests: 125 Clq binding assay (Clq-BA), conglu-
tinin binding test (CGB-SP) and precipitation in 3.5% polyethilenglycol
(PEG), each of these revealing different types of CIC. The CIC
precipitated by PEG were further investigated by double radial
immunodiffusion (DRID) in agarose gel, against monospecific sera anti
IgG, IgA, 1gM, Clq, C1, C3, C4, and by ultracentrifugation (16 hr at
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x87,000g) in linear 10 to 40% sucrose gradient, to evaluate their
molecular weight, using as markers human IgG (7S), 1gM (l9S), and
catalase (11 ,2S). Every test revealed CIC with different frequency: Clq-
BA more often in MGN (38.9%) and in FGS (33.3%), CGB-SP in MGN
(44.4%) and in MPGN (44.4%), and PEG in MCGN (71.4%). Very
rarely were all three tests simultaneously positive. In different histolog-
ic types of PGN, the ultracentrifugation showed CIC of various mol
wts, and frequently the contemporary presence of CIC of different mol
wts. In CIC precipitated by PEG, 1gM, and Clq were observed in
MCGN, while IgG and complement were revealed more frequently in
other PGN; IgA were rarely found, also in MSPGN with mesangial
predominant IgA deposits. In conclusion, our studies showed different
CIC for composition, mol wt, and biological activities in PGN, some-
times in relation to histologic lesions. In addition the comparison
between CIC investigated by DRID and immune complexes (IC)
revealed by immunofluorescence in renal biopsies frequently showed
differences. Furthermore, this result is suggestive for IC formed in
some types of PGN at the renal level.
Acid-base balance on peritoneal dialysis with acetate and lactate
buffers. G. La Greca, S. Biasioli, S. Cortesi, A. Fabris, M. Feriani, E.
Pisani, C. Ronco, and F. Zen. Divisione di Nefrologia e Dialisi e
Laboratorio di Analisi Chimico-Cliniche, Ospedale S. Bortolo, Vicen-
za, Italy. To evaluate acid-base balance on intermittent peritoneal
dialysis (IPD) and on continuous ambulatory peritoneal dialysis
(CAPD), 40 studies were performed on 20 patients under conditions of
IPD with acetate buffer (5 patients), IPD with lactate buffer (5 patients),
CAPD with acetate buffer (5 patients), and CAPD with lactate buffer (5
patients). Commercial dialysis solutions containing 41.5 m acetate and
43.7 mri lactate for LPD were utilized; 38.5 m was the content both of
acetate and lactate for CAPD. Acetate, lactate, and pyruvate concen-
trations in blood and dialysate were determined at different times (0, 30,
60, 120, 240, and 480 mm) of intermittent dialysis; blood samples for
blood gas analysis were also drawn at the same time. Blood and
dialysate samples were taken at the end of each exchange (4 to 5 per
day) for 6 to 7 days a week in patients on CAPD. Calculations for
acetate, lactate, and bicarbonate kinetics of IPD and CAPD conformed
with those of Tolchin (1977) and consequently "adapted" to PD. Thus,
it was possible to quantify the balance of the buffers, their mass transfer
rate, the bicarbonate generated, and the percentage of buffer converted
to bicarbonate. IPD kinetics of acetate and lactate are similar, the main
difference being a lower and significant percentage of lactate converted
to bicarbonate (45%) in comparison to acetate one (71%). On CAPD,
the kinetics of the two buffers are quite different: while the serum
lactate level was found constantly low (mean 0.97 0.33 mmoles/liter),
the acetate showed constant high levels (5.12 3.34 mmoles/liter).
Thus there is a different utilization of the two buffers between the
"acute intermittent" treatment (IPD) and "continuous" one (CAPD).
While on IPD, there are not any important differences between the two
buffers. On CAPD, lactate seems to be better and safer than acetate, for
instance, serum bicarbonate values are very constant with lactate (27.7
2.13 mmoles/liter) while with acetate there resulted a certain trend to
exceed physiologic values (29.5 1.7 mmoles/liter). When used,
acetate concentration in the dialysate for CAPD must be less than 38.5
mmoles/liter.
Natural history of calcium nephrollthlasls in Italy. F. Masi, E. Rovelli,
F. Malberti, N. Colleoni, G. Colussi, L. Luciani, and M. Surian.
Divisione di Nefrologia e Dialisi degli Ospedali Ca'Granda e S. Carlo
Borromeo, Milano, Italy. Little is known about the natural history of
calcium nephrolithiasis in Italy. Most of the known studies on this topic
have been performed in foreign populations, with different socioeco-
nomic and dietetic habits. We have retrospectively studied 476 stone
formers out of 4846 ambulatory nephropathic patients from two differ-
ent nephrologic centers. Calcium stones (oxalate and/or phosphate)
were present in 290(69.7%) patients, of whom 58% were males and 42%
females. Complete metabolic and clinical data were available in 200 of
these patients: 41% had idiopathic hypercalciuria (IH), 7.5% hyperuri-
cosuria (HU), 13.5% lB + HU, 5.5% primary hyperparathyroidism
(HP), 3.5% sponge kidney, 9% urinary tract malformations, 1.5% renal
tubular acidosis (the last three groups were not considered further);
18.5% of patients had no clinical or metabolic disturbance (NMD). IH
and HU were prevalent in males (76.3%) and HP in females (64.3%).
Mean age at onset was in the 3rd to 4th decade of life, and was slightly
later in hyperuricosuric patients. Number of stones/patient/year was
higher in patients with HP and lower in patients with NMD. Calcium
nephrolithiasis had a high recurrence rate (after 10 years followup 74%
of patients had at least one recurrence and 60% had 3 or more stones
formed); 40% of recurring patients had their first recurrence within one
year from the first stone and most of these patients had a second
recurrence in the following year. Clinical history and metabolic evalua-
tion help to select patients at high risk of recurrence, in whom treatment
is indicated.
Serum ferritin in hemodialyzed patients: Correlations with other
parameters of anemia. S. Mombelloni, E. Movilli, G. Pizzocolo, M.
Ravelli, M. Campanini, G. Cancarini, L. Ascari, A. Albert mi, and R.
Majorca. Divisione di Nefrologia e Dialisi, II Laboratorio di Anal isi
chimico-cliniche e Lahoratorio di Ormonologia e Toss icologia, Spedali
Civili, Brescia, Italy. We have studied 51 hemodialyzed patients (30
males, 31 females) undergoing regular dialysis therapy (RDT) from 0.7
to 14 years (mean, 5.9 years) receiving about 100 mg per month of Fe
gluconate i.v. We evaluated the patients monthly for one year follow-
ing: serum ferritin, transferrin, % TIBC, hematocrit (Hct), hemoglobin
(Hb). Serum ferritin concentrations in RDT patients were significantly
higher (P < 0.001) than in normal subjects, even when considered
without iron therapy. The normal difference between sexes disappears.
In our cases, serum ferritin shares a direct correlation with serum iron,
an inverse correlation with transferrin, a direct correlation with %
TIBC, and only in males, an inverse correlation with Hb and Hct.
Serum ferritin levels are still high after 6 months from the withdrawal of
iron therapy, and rise promptly after starting treatment. The reason
serum ferritin shares an inverse correlation with Hb and Hct could be
that patients with lower ferritin and higher Hct are those who are able to
metabolize iron more easily; the reasons for this are obscure. The fact
that this trend is shown only by males could be due to the higher levels
of testosterone in this population. Serum ferritin seems to be the best
guide to iron supplementation in RDT patients.
Effect of sodium intake on plasma norepinephrine, renin activity and
their responses to head-up tilt in essential hypertension. A. Morganti, T.
Pickering, J. Lopez-Ovejero, and J. Laragh. Is! ituto di Ricerche
Cardiovascolari, CNR, Milano, Italy, and The New York Hospital
Cornell Medical Center, New York. Because the state of sodium
homeostasis is reported to affect plasma norepinephrine (NE), which
reflects the activity of the sympathetic nervous system (SNS), and this
last is known to control the renin response to various stimuli, our aim in
this study was to examine (1) whether the changes in plasma renin
activity (PRA) induced by different sodium intakes are associated with
concomitant changes in NE, and (2) whether the state of sodium
balance influences the responses of NE and PRA to a neural stimulus
such as the assumption of upright posture. Thus, we measured NE and
PRA in 8 patients with uncomplicated essential hypertension both in the
supine position and after 30 mm of 65° head-up tilt after 5 days on low
(L), medium (M), and high (H) sodium intake (10, 100, and 300
mEq/day, respectively). In the supine position, NE was similar on L
and M (312 49 and 334 35 pg/mI) while it was significantly lower on
H (200 32 pglml) (P < 0.01 for both L and M); in contrast PRA was
always different (L, 5.7 2.2; M, 2.9 1.1; H, 0.9 0.4 ng/ml/hr) (P <
0.05 at least). After 30 mm of tilt, the increments in NE were similar (L,
419 103; M, 268 46; H, 346 87 pglml) while those in PRA were
different in absolute values (L, 4.8 2.0; M, 2.4 1.0; H, 0.5 0.2
nglml/hr) (P < 0.01 for all) but similar when expressed in percent of
supine values (L, 83 13; M, 89 14; H, 73 21%). These data show
that H decreases both basal NE and PRA whereas L increases PRA
only; thus, while the responses of the SNS and of renin to sodium
loading may be related, that of renin to sodium deprivation is probably
mediated through nonneural mechanisms. Also, it appears that neither
the responsiveness of the SNS nor that of renin to head-up tilt are
influenced by the state of sodium balance.
Hemodialysis-induced leukopenia: Role of direct cell-to-membrane
interaction. A. Pacitti, G. Segoloni, G. Triolo, C. Tetta, M. Messina, F.
Bussolino, G. Camussi, R. Ragni, P. F. Martini, R. Coppo, and A.
Vercellone. Cattedra di Nefrologia deli' Universitd e Divisione di Ne-
frologia e Dialisi, Ospedale 5G. Battista, Torino, Italy. Extracorporeal
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circulation during hemodialysis results in a transient, profound neutro-
penia, which has been related to intravascular polymorphonuclear
neutrophil (PMN) aggregation with ensuing leukostasis and leukoembo-
lization, particularly in the pulmonary microvasculature. Although C5a
anaphylatoxin and its carboxypeptidase B-derived desarginated prod-
uct C5a des Arg are in vitro able to mediate PMN aggregation, their role
in vivo remains to be defined, as during hemodialysis complement
activation occurs late and in vitro is rather slow (45 mm) as compared
with the fugacity (5 to 30 mm) of hemodialysis-induced neutropenia.
Our studies could explain these discrepancies, suggesting the possibility
of a direct cell-to-membrane interaction. In vitro purified human PMN,
incubated with cuprophan but not with polyacronitrile membranes,
release their lysosomal enzymes and cationic proteins (CP), which are
capable of inducing PMN aggregation. As for C5a, CP are in vivo
cleaved to CP des Arg by serum carboxypeptidase B. Recently, we
demonstrated both in vitro and in vivo that C5a-, CSa des Arg-, CP and
CP des Arg-induced PMN aggregation is triggered by a final, common,
effector substance platelet-activating factor (PAF), a low molecular
weight phospholipid, with a potent aggregating activity on platelets
leading to the release of their granular content. PAF is fully active on
PMN as on platelets in the presence of ADP scavengers and cyclo-
oxygenase inhibitors, thus suggesting activation of a unique metabolic
pathway independent from the other known pathways of PMN aggrega-
tion, that is, the ADP and arachidonic acid/thromboxane A2-mediated
pathways. PAF-induced PMN aggregation is completely and selectively
inhibited by lipid-soluble drugs such as glucocorticoids (6-methyl-
prednisolone). The present study concerns the in vitro effect of cupro-
phan membrane on purified human PMN. Our data show that PMN in
the presence of cuprophan but not of polyacronitrile undergo a process
of degranulation, and PAF is released in the supernatant. The interac-
tion between dialysis membrane and cells leading to the release of
neutrophil aggregant activity is related to its biologic properties.
However, complement activation and release of neutrophil aggregant
activity are two processes that occur independently and can therefore
be studied separately.
Calcium metabolism in nephrotic syndrome of children. F. Perfumo,
R. Oleggini, R. Gusmano. Divisione di Nefrologia e Dialisi, istituto G.
Gaslini, Genova, Italy. Patients with nephrotic syndrome (NS) have
several disorders of calcium metabolism. These include hypocalcemia,
hypocalciuria, and decreased intestinal absorption of calcium. Vitamin
D circulates bound to a low-molecular weight protein, and urinary loss
of the globulin might contribute to the development of calcium abnor-
malities. We studied 16 patients, 2 to 14 years of age, with normal renal
function and proteinuria (100 mg/m2/hr), at the clinical onset of NS. The
parameters evaluated were: Ca, P, Mg, alk. phosphatase, PTH, calcito-
nm, 25-OHCC, Ge-globulin in serum and Ca, P, and OH-proline on 24-
hr urine collections. The results showed: (a) a significant reduction of
serum calcium, urinary calcium, vitamin D-binding globulin, and 25-
OHCC; (b) a rise in serum PTH, in particular 6/16 children had PTH
values above 1 ng/ml; (c) a direct and significant correlation between
blood Ge-globulin and serum albumin and an inverse significant relation
between blood Ge-globulin and the degree of proteinuria. We conclude:
(I) abnormalities of calcium metabolism in NS appear early in the
course of the disease; (2) therapeutic implications are important to
avoid damage to a growing skeleton.
C3d assay in idiopathic and secondary glomerulonephritis. G. Pertosa,
C. Pecoraro, E. La Raia, P. Stanziale, R. Gallo, V. E. Andreucci, and
F. P. Schena. istituto di Clinica Medica II deli' Universitâ di Ban.
Cattedra di Nefrologia Medica della II Facoltd di Medicina deli' Uni-
versitâ di Napoli, Italy. The behavior of the complement system is
routinely evaluated by measuring C3 with radial immunodiffusion.
Truly, this method may indicate a normal value if its accelerated
catabolism is counterbalanced by an increased synthesis. In contrast,
the assay of C3d, the stable fragment of C3, could reveal the participa-
tion of the complement system even in those cases where there are
normal serum levels of C3. Thus, C3d values have been investigated in
74 patients with idiopathic glomerulonephritis (GN) and in 31 cases of
secondary GN. Results have shown significant high levels of C3d in
different idiopathic GN with normal C3 values. The incidence of
increased C3d levels varied from 35% in cases of endoextracapillary
GN, to 51% in patients with membranoproliferative GN. Two different
behaviors of C3d and C3 levels were found in secondary GN: a) high
levels of C3d associated with normal C3 levels in 30 to 57% of the GN,
(b) normal C3d values associated with reduced levels of C3. These data
suggest that in idiopathic and secondary GN with normal C3 values and
high levels of C3d, the activation of the complement system is probably
masked by an increased synthesis of C3, whereas in secondary GN with
low levels of C3 and normal values of C3d, the activation of the
complement system is associated to insufficient synthesis of C3.
Therefore, C3d measurement is a valid parameter for revealing the
activation of the complement system and low synthesis of C3.
Rheumatoid kidney. M. Ragaiolo, R. Boggi, A. Corvetta, E. Lom-
bardo, A. Martino, V. Mioli, R. Montironi, and C. Parravicini. Cat-
tedre di Patologia Medica, di Anatomia umana normale, di Anatomia
Patologica e di Nefrologia dell'Universitd. Divisione di Nefrologia e
Dialisi, Ospedale LJmberto 1", Ancona, italy. In 35 patients affected by
chronic rheumatoid arthritis (ARA's and Stenbrocker's criteria were
used for the diagnosis), we have studied the "rheumatoid kidney".
Excluding all the patients who previously suffered from complications
(that is, urinary stones and infections) or treated by phenacetin and gold
therapy, we have selected 17 patients. All were submitted to clinical,
functional, and metabolic investigations, and, in 8 of them, to hystolog-
ic observations (light, immunofluorescence, and electronic) by renal
biopsy. Clinically we have observed microscopic haematuria and slight
proteinhiria in 16 cases; 1 case with no pathologic urinary findings and
no cases with a nephrotic or acute nephritic syndrome. Histologically
we have observed by light microscopy some glomerular damages, that
is, focal or diffuse mesangial hypercellularity in all the cases, segmental
thickening of the capillary walls in 4 cases, intimal arteriolar thickening
in 4 cases, and in all the cases a slight atrophy of the tubules with focal
interstitial fibrosis and linphomonocyte infiltration. By the immunofiuo-
rescence observations, granular deposits of the fibnnogen in the
capillary walls (3 cases), of 1gM (4 cases) and of C3 (1 case), were
observed. IgG and IgA were always negative and a slight fibrinogen
positivity on the tubular walls was noted in 3 cases. Electron micro-
scopic picture confirmed the focal mesangial increase (cells and matrix)
in all the cases, endothelial proliferation in I case, no dense deposits in
capillary walls, splitting of the tubular walls in 4 cases, focal increase in
collagen interstitial fibers in all the cases. By these observations we can
conclude that the rheumatoid kidney has some slight polymorphic
lesions but no pathognomonic picture. Simultaneously, a significant
correlation between the clinical and hystological pattern and the
positivity of the serological screening was noted.
Nephritic factor in membranoproliferative glomerulonephritis. P.
Stanziale, G. Pertosa, C. Pecoraro, E. Vox, R. Gallo, C. Grasso, F. P.
Schena, and V. E. Andreucci. Cattedra di Nefrologia Medica della
Facoltà di Medicina dell'Universitd, Napoli. Istituto di Clinica Medica
II deil'Universila, Ban, Italy. Nephritic factor (NeF) has been detected
in various types of glomerulonephritis, its highest incidence being in
membranoproliferative glomerulonephritis (MPGN). Up to now, nei-
ther a clear pathogenic nor a meaningful prognostic role of NeF has
been elucidated. In this study, NeF was looked for by immunoelectro-
phoretic and hemolytic methods in 24 patients with primary MPGN (18
type I, 6 type II) and in II patients with secondary MPGN. Inimuno-
chemical dosage of complement fractions (Clq, C4, C3, C3d) and of
properdin factor B was carried out. NeF was found in 5 patients (28%)
with type I and in 3 patients (50%) with type II MPGN. NeF was
associated with low levels of C3 in 3 out of S patients with type! MPGN;
in all these patients, however, C3d was elevated. C4, instead, was
normal, while Clq fluctuated from low to normal values. C3 was low in
6, and normal in 4 out of 10 NeF-negative patients. In all NeF-positive
patients with secondary MPGN (1 with LES, 4 with primary cryoglobu-
linemia), low values of Clq, C4, C3, and properdin factor B were found.
Quantitative measurements of NeF at regular intervals throughout the
study showed consistent changes in the NeF concentration in many
patients and a complete, although transient, disappearance of NeF in 4
patients. A significant relation between NeF and the course of renal
disease was observed only in 3 patients with type I! MPGN, in which
the existence of NeF was associated with a progressive and rapid
worsening of renal function. Conclusions. NeF is particularly frequent
both in primary and in secondary type II MPGN. In the latter, NeF
indicates a poor prognosis.
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Lupus nephropathy: Involvement of coagulation in blood, tissues and
urine. P. Stratta, C. Canavese, M. Dogliani, M. Messina, M. Rotunno,
and A. Vercellone. Divisione di Nefrologia e Dialisi, Ospedale S.G.
Battista, Cattedra di Nefrologia dell'Universitá, Torino, Italy. During
systemic lupus erythematosus (SLE), the involvement of the coagula-
tion system can be due to two possible pathogenetic mechanisms: the
activation of the coagulation and fibrinolitic cascade unleashed by
immunological processes and the formation of antibodies against
omeostasis factors. We studied a first group of patients including 21
subjects with nephropathy due to SLE. Renal biopsies were performed
and patients were classified according to Appel: 2 in class II, 2 in class
III, 13 in class IV, 2 in class V, 2 in class VI. Results were compared
with a second group (14 SLE patients) with systemic onset and scarse
renal involvement and a third group of 70 patients with primary
glomerulonephritis with different hystopathologic picture. The follow-
ing parameters were studied: Quick time, PTT, TEG, fibrinogen and
platelet blood level, dripping time, spontaneous and DPA-induced
platelet aggregation according to Breddin, collagen, adrenalin, ristoce-
tin, platelet adhesiveness, urinary and tissue fibrinolysis, blood and
urinary FDP, schistocytes in peripheral smear, paracoagulation test,
blood and urinary level of endoplatelet release products (endoplatelet
factor 4 and -l-thromboglobulin). Signs of a systemic activation of
coagulation that are frequent during the acute stage of systemic Lupus
(80.9%) appear only sporadically in SLE with prevailing renal involve-
ment and never in primary glomerulonephritis. Platelet pathology
(absent in primary glomerulonephntis) is commonly found in SLE
(70%) and in renal lupus erythematosus (40%): reduced response to
aggregating agents, reduced adhesiveness and presence of antiplatelet
antibodies; the latter two are found independently of the clinical stages
of the disease in systemic LE and they disappear during remission in
renal lupus erythematosus. Circulating anticoagulants are rare (7%) and
appear only during the acute stage of the systemic disease; they
disappear during remissions. Tissue fibrinolysis evaluated with the
Todd Pandolfi hystochemical method resulted constantly high in lupus
nephropathies while it was normal or low in primary glomerulonephri-
tis. Urinary fibrinolysis is normal while urinary FDP are often high also
in primary glomerulonephritis. Our results do not prove a systemic or
local activation of coagulation during primary glomerulonephritis: in
nephropathies due to SLE, a local activation is reported but signs in
blood are less marked than in systemic LE.
Effect of captopril on blood pressure, plasma renin activity and
autonomic nervous system in low-normal renin essential hypertension. A.
Sturani, C. Chiarini, E. Degli Esposti, A. Gattiani, A. Masi, A.
Santoro, A. Umile, A. Zuccalä, and P. Zucchelli. Divisione di Nefrolo-
gia e Dialisi, Ospedale M. Malpighi, Bologna, Italy. Captopnl was
administered to 12 essential hypertensive patients with low-normal
renin in order to test its effectiveness in reducing blood pressure (BP)
and to determine whether the inhibition of converting enzyme (CE)
could interfere with sympathetic neural activity. Captopril, at a daily
dose of 150 to 450 mg, significantly reduced BP in 5 patients (respond-
ers) and had no effect in 7 patients (nonresponders). In the responders,
a significant reduction in mean arterial pressure (MAP) was already
observed with a daily dose of 75 mg (from 127 11 to 119 14mm Hg,
P <0.05) and a further significant reduction was observed at the end of
treatment (from 127 11 to Ill 11 mm Hg, P < 0.01). In the
nonresponders, no significant variation in MAP was observed (from 132
10 to 128 11 mm Hg). A significant fall in resting heart rate (HR)
was observed both in responders and nonresponders on 75 mg daily
(from 70.8 4.2 to 65.4 4.0 beats/mm, P < 0.01 and from 77.0 4.1
to 73.7 3.8 beats/mm, P < 0.05, respectively). This fall remained
significant in the responders, while it was lost in the nonresponders at
the end of treatment. The drug did not significantly change plasma renin
activity in any patient. Plasma noradrenaline was significantly reduced
by captopril in the responders (from 531 81 to 210 26 ng/liter, P <
0,05) and remained unchanged in the nonrespnders (from 231 36 to
248 45 ng/liter). The response of BP and HR to Valsalva maneuver,
tilt test, mental stress test, and cold-pressure test was similar before and
after treatment in all patients. On the contrary, the bradycardia induced
by diving test was significantly greater after treatment than before
therapy (from 21 3 to 29 4 beats, P < 0.05 in the responders, and
from 32 11 to 38 9 beats, P < 0.05 in the nonresponders). In
conclusion, captopril also normalizes BP in patients with low-normal
renin essential hypertension. The effect of CE inhibition plasma nor-
adrenaline and BP suggests that captopril may interfere with the release
of catecholamines, and this interference may contribute to the hypoten-
sive effect of the drug. The physiologic study suggests an overall
integrity of the baroreceptor reflex arc and vascular reactivity to stress
before as well as after treatment with captopril. The drug decreases
resting HR and enhances the bradycardia induced by diving test,
suggesting that captopril may cause overactivity of the parasympathetic
system.
Vitamin D metabolites in patients with early renal failure: Effects of
dietary phosphate restriction and calcium supplementation. N. Tessitore,
B. Lund, B. Lund, 0. H. Sorensen, E. Bonucci, G. Maschio. Divisione
di Nefrologia, Istituti Ospitalieri, Verona e I Cattedra di Anatomia
Patologica dell'Universitâ, Roma, Italy, and Department of Orthope-
dic Surgery, Frederiksborg Hospital, Hillerod, and Department of
Medicine E and F, Copenhagen, Denmark. In 20 patients with early
renal failure (GFR, by iothalamate clearance, 23 to 63 mI/mm), we have
evaluated the serum values of vitamin D metabolites and bone histology
before and after 8 months of a diet containing 700 mg of phosphate and
600 mg of calcium. In 10 of them, oral calcium supplementation (1,000
mg) was added. The basal values of plasma calcium and phosphate were
normal, i-PTH values were only mildly increased (2.95 1.27 mU/mI;
normal range, 1 to 2.4), serum levels of 25(OH)D3 were in the low-
normal range, while serum concentration of 1.25 (OH)2D3 and
24,25(OH)2D3 were significantly reduced in comparison with controls
(10.02 8.61 pg/mI and 0.87 0.84 ng/ml, respectively; normal range,
18 to 48 pg/mI for I .25(OH)2D3 and 0.6 to 2.3 ng/ml for 24,25(OH)2D3).
Bone biopsy showed normal histology in 45% of our patients, osteoma-
lacia in 30%, and osteomalacia and increased resorption in 25% of them.
No correlation was found between bone histology and both PTH and
vitamin D metabolites levels. The only significant correlation was found
between 25(OH)D3 and 24,25(OH)2D3 values (r = 0.56). After the
treatment, there were no significant changes in GFR, plasma calcium
and phosphate, i-PTH, 25(OH)D3, 1 ,25(OH)2D3 and bone histology,
while 24,25(OH)2D3 levels were significantly increased in those patients
treated with calcium supplementation too (from 0.73 0.72 to 1.66
0.59 ng/ml; P < 0.025). Moreover, in the same patients the correlation
between 25(OH)2D3 and 24,25(OH)2D3 was stricter (r = 0.92). Our data
show an impaired 1-alfa-hydroxylation even in the early phases of renal
failure and suggest that the normal levels of 24,25(OH)2D3 could explain
the mild degree of hyperparathyroidism and bone lesions found in those
patients with incipient renal failure early treated with a phosphate-
restricted diet and calcium and vitamin D supplements.
